<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912584</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1038</org_study_id>
    <nct_id>NCT03912584</nct_id>
  </id_info>
  <brief_title>Study Comparing the P200TE and the P200TxE in Glaucoma Patients</brief_title>
  <official_title>Qualitative OCT Image Grading Study Comparing the P200TE and the P200TxE in Glaucoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optos, PLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the image quality between two OCT devices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to collect OCT scans to compare the qualitative B scan images&#xD;
      produced by the P200TxE to the P200TE device in glaucoma subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative B-Scan Assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Results of a qualitative assessment of the B scans from each device from three independent masked and qualified graders using a four point scale (0-3) related to assessing retinal structures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment from Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of safety will be assessed through adverse events reported by the site and documented on each subject's case report form.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Optical Coherence Tomographer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>P200TE</intervention_name>
    <description>The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.</description>
    <arm_group_label>Optical Coherence Tomographer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>P200TxE</intervention_name>
    <description>The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.</description>
    <arm_group_label>Optical Coherence Tomographer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects 22 years of age or older who have full legal capacity to&#xD;
             volunteer on the date the informed consent is signed;&#xD;
&#xD;
          -  Subjects who can follow the instructions by the clinical staff at the clinical site,&#xD;
&#xD;
          -  Subjects who agree to participate in the study;&#xD;
&#xD;
          -  Subjects who have been diagnosed with glaucoma in the study eye as confirmed by the&#xD;
             investigator;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects unable to tolerate ophthalmic imaging;&#xD;
&#xD;
          -  Subjects with ocular media not sufficiently clear to obtain acceptable OCT images;&#xD;
&#xD;
          -  Subjects with any clinically significant ocular pathology except glaucoma, as&#xD;
             determined by self-report and/or investigator assessment on the day of the study&#xD;
             visit;&#xD;
&#xD;
          -  Subjects who are not reliably tested with at least one Humphrey Field Analyzer (HFA)&#xD;
             visual field (24-2 or 30-2, white on white) measured on the day of the study visit or&#xD;
             within the previous year from the study visit, defined as fixation losses &gt; 20% or&#xD;
             false positives &gt; 33%, or false negatives &gt; 33%;&#xD;
&#xD;
          -  Subjects with history of dementia or multiple sclerosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 21, 2021</submitted>
    <returned>July 12, 2021</returned>
    <submitted>July 30, 2021</submitted>
    <returned>August 24, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

